BR112015002249A2 - composto, um estereoisômero ou sal farmaceuticamente aceitável do mesmo; composição farmacêutica; método para tratar um estado associado a receptor de adenosina a2a em um indivíduo; método para diagnosticar anormalidades de perfusão de miocárdio em um mamífero; e método para reduzir a pressão interocular em um indivíduo - Google Patents

composto, um estereoisômero ou sal farmaceuticamente aceitável do mesmo; composição farmacêutica; método para tratar um estado associado a receptor de adenosina a2a em um indivíduo; método para diagnosticar anormalidades de perfusão de miocárdio em um mamífero; e método para reduzir a pressão interocular em um indivíduo

Info

Publication number
BR112015002249A2
BR112015002249A2 BR112015002249A BR112015002249A BR112015002249A2 BR 112015002249 A2 BR112015002249 A2 BR 112015002249A2 BR 112015002249 A BR112015002249 A BR 112015002249A BR 112015002249 A BR112015002249 A BR 112015002249A BR 112015002249 A2 BR112015002249 A2 BR 112015002249A2
Authority
BR
Brazil
Prior art keywords
individual
stereoisomer
mammal
treating
pharmaceutically acceptable
Prior art date
Application number
BR112015002249A
Other languages
English (en)
Inventor
Beauglehole Anthony
Wang Guoquan
Thompson Robert
Original Assignee
Lewis And Clark Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lewis And Clark Pharmaceuticals Inc filed Critical Lewis And Clark Pharmaceuticals Inc
Publication of BR112015002249A2 publication Critical patent/BR112015002249A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)

Abstract

resumo composto, um estereoisômero ou sal farmaceuticamente aceitável do mesmo; composição farmacêutica; método para tratar um estado associado a receptor de adenosina a2a em um indivíduo; método para diagnosticar anormalidades de perfusão de miocárdio em um mamífero; e método para reduzir a pressão interocular em um indivíduo” a presente invenção fornece n-alquil 2-(dissubstituída)alquiniladenosina-5'-uronamidas e derivados das mesmas e composições farmacêuticas que contêm as mesmas que são agonistas seletivos de receptores de adenosina a2a (ars). esses compostos e composições são úteis como agentes farmacêuticos. 1/1
BR112015002249A 2012-08-01 2013-07-31 composto, um estereoisômero ou sal farmaceuticamente aceitável do mesmo; composição farmacêutica; método para tratar um estado associado a receptor de adenosina a2a em um indivíduo; método para diagnosticar anormalidades de perfusão de miocárdio em um mamífero; e método para reduzir a pressão interocular em um indivíduo BR112015002249A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261678605P 2012-08-01 2012-08-01
US201361787188P 2013-03-15 2013-03-15
PCT/US2013/053053 WO2014022577A1 (en) 2012-08-01 2013-07-31 N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as a2a agonists

Publications (1)

Publication Number Publication Date
BR112015002249A2 true BR112015002249A2 (pt) 2017-07-04

Family

ID=50025663

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015002249A BR112015002249A2 (pt) 2012-08-01 2013-07-31 composto, um estereoisômero ou sal farmaceuticamente aceitável do mesmo; composição farmacêutica; método para tratar um estado associado a receptor de adenosina a2a em um indivíduo; método para diagnosticar anormalidades de perfusão de miocárdio em um mamífero; e método para reduzir a pressão interocular em um indivíduo

Country Status (15)

Country Link
US (1) US9067963B2 (pt)
EP (1) EP2879683B1 (pt)
JP (1) JP6545618B2 (pt)
KR (1) KR20150036767A (pt)
CN (1) CN104582709A (pt)
AU (1) AU2013296420B2 (pt)
BR (1) BR112015002249A2 (pt)
CA (1) CA2880040A1 (pt)
EA (1) EA027174B1 (pt)
IL (1) IL236986A (pt)
IN (1) IN2015DN00538A (pt)
MX (1) MX367879B (pt)
NZ (1) NZ703992A (pt)
WO (1) WO2014022577A1 (pt)
ZA (1) ZA201501350B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1888548B1 (en) 2005-05-26 2012-08-22 Neuron Systems, Inc Quinoline derivative for the treatment of retinal diseases
US9822141B2 (en) * 2012-08-01 2017-11-21 Lewis And Clark Pharmaceuticals, Inc. N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as A2A agonists
RU2676694C9 (ru) 2013-01-23 2019-06-25 Альдейра Терапьютикс, Инк. Заболевания, связанные с токсичным альдегидом, и их лечение
JP6947406B2 (ja) 2015-08-21 2021-10-13 アルデイラ セラピューティクス， インコーポレイテッド 重水素化化合物およびその使用
AU2017264697A1 (en) 2016-05-09 2018-11-22 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
EP3596040B1 (en) 2017-03-16 2023-10-11 Aldeyra Therapeutics, Inc. Polymorphic salt of 6-chloro-3-amino-2(2-hydroxypropyl)quinoline and uses thereof
MX2020003425A (es) 2017-10-10 2020-07-29 Aldeyra Therapeutics Inc Tratamiento de trastornos inflamatorios.
WO2020223685A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
WO2020253866A1 (zh) * 2019-06-21 2020-12-24 中国人民解放军军事科学院军事医学研究院 腺苷类化合物、其可药用盐或其立体异构体及用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
JPS6299395A (ja) 1985-10-25 1987-05-08 Yamasa Shoyu Co Ltd ２−アルキニルアデノシンおよび抗高血圧剤
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
JPH02104783A (ja) * 1988-10-11 1990-04-17 Kanai Hiroyuki スチールコードおよびタイヤ
EP0444196B1 (en) 1988-11-15 1994-06-08 Yamasa Shoyu Kabushiki Kaisha Agent for treatment and prophylaxis of ischemic disease of heart or brain
KR920700218A (ko) 1989-06-20 1992-02-19 원본미기재 2-알키닐 아데노신의 합성중간체, 그 합성 중간체의 제조법, 그 합성중간체를 이용한 2-알키닐 아데노신의 제조법 및 안정한 2-알키닐 아데노신 유도체
US5189027A (en) 1990-11-30 1993-02-23 Yamasa Shoyu Kabushiki Kaisha 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases
JP3025557B2 (ja) * 1991-06-28 2000-03-27 ヤマサ醤油株式会社 ２‐アルキニルアデノシン誘導体
IT1254915B (it) 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
JP2002173427A (ja) * 1998-09-01 2002-06-21 Yamasa Shoyu Co Ltd 眼疾患治療用医薬組成物
US6322771B1 (en) * 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
MXPA02009258A (es) 2000-03-23 2005-04-19 Solvay Pharm Bv Derivados de 4,5-dihidro-1h-pirazol que tienen actividad antagonistica de cannabis-1.
AU2002362443B2 (en) 2001-10-01 2008-05-15 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
EP1537135B1 (en) 2002-09-09 2009-11-25 Cv Therapeutics, Inc. Adenosine a3 receptor agonists
NZ585697A (en) 2004-08-02 2011-12-22 Univ Virginia Patent Found 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
US7601723B2 (en) * 2005-02-25 2009-10-13 Pgx Health, Llc Pyridyl substituted xanthines
WO2007120972A2 (en) 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
ATE500263T1 (de) * 2006-06-27 2011-03-15 Cbt Dev Ltd Neue 2',3'-methylidenacetyladenosine prodrugs zur verwendung als adenosinrezeptoragonisten
US20080312160A1 (en) 2007-04-09 2008-12-18 Guerrant Richard L Method of treating enteritis, intestinal damage, and diarrhea from c. difficile with an a2a adenosine receptor agonist
JP5349461B2 (ja) 2007-05-17 2013-11-20 ギリアード・パロ・アルト・インコーポレイテッド Ａ２ａ−アデノシン受容体アゴニストおよびその多形体を調製するための方法
US8293720B2 (en) 2007-12-20 2012-10-23 Dogwood Pharmaceuticals, Inc. Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
US8058259B2 (en) 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
JP2012532140A (ja) * 2009-06-30 2012-12-13 フォレスト・ラボラトリーズ・ホールディングス・リミテッド Ａ２ａｒ作動薬としてのアルコキシ−カルボニル−アミノ−アルキニル−アデノシン化合物及びその誘導体

Also Published As

Publication number Publication date
EA201590205A1 (ru) 2015-06-30
AU2013296420B2 (en) 2017-12-07
AU2013296420A1 (en) 2015-02-12
CN104582709A (zh) 2015-04-29
EP2879683A1 (en) 2015-06-10
KR20150036767A (ko) 2015-04-07
US20140037538A1 (en) 2014-02-06
JP6545618B2 (ja) 2019-07-17
MX367879B (es) 2019-09-10
EA027174B1 (ru) 2017-06-30
IN2015DN00538A (pt) 2015-06-26
EP2879683A4 (en) 2016-04-20
NZ703992A (en) 2018-04-27
US9067963B2 (en) 2015-06-30
ZA201501350B (en) 2016-12-21
JP2015524440A (ja) 2015-08-24
WO2014022577A1 (en) 2014-02-06
MX2015001370A (es) 2016-04-26
IL236986A (en) 2017-06-29
EP2879683B1 (en) 2020-01-22
CA2880040A1 (en) 2014-02-06

Similar Documents

Publication Publication Date Title
BR112015002249A2 (pt) composto, um estereoisômero ou sal farmaceuticamente aceitável do mesmo; composição farmacêutica; método para tratar um estado associado a receptor de adenosina a2a em um indivíduo; método para diagnosticar anormalidades de perfusão de miocárdio em um mamífero; e método para reduzir a pressão interocular em um indivíduo
BR112014029115A8 (pt) Composto, composição farmacêutica, e, uso de um composto ou composição
EA201891509A1 (ru) Способы лечения рака
CY1120159T1 (el) Ενωσεις που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα
BR112015007698A2 (pt) Composto, composição farmacêutica, e, uso de um composto
MX362442B (es) Inhibidores de enzima 1 dependiente de inositol (ire-1alfa).
BR112015016585A2 (pt) Compostos radiofarmacêuticos baseados em triazina, complexos de metal e composição farmacêutica compreendendo os referidos complexos
BR112016029582A2 (pt) derivados de exendina-4 como agonistas de receptor de glucagon seletivos
WO2015054500A3 (en) Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
CL2015002402A1 (es) Sales de derivados de 2-amino-1-hidroxietil-8-hidroxiquinolin-2(1h)-ona que tienen actividad agonista del receptor b2 adrenergico asi como actividad antagonista del receptor muscarínico m3.
UY35684A (es) Formulación de inhibidores de la tirosina quinasa de bazo (syk)
WO2007098474A8 (en) Phenyl-cycloalkyl and phenyl-heterocyclic derivatives as s1p receptor agonists
BR112016015236A2 (pt) inibidores de serina/treonina quinase
BR112016002459A2 (pt) Derivados de benzimidazolil-metil ureia como agonistas receptores de alx
CL2011000237A1 (es) Compuestos adecuados para marcar o ya marcados con 18f , derivados d epiridina, ligando del receptor periferico de benzodiazepina para el diagnostico por imagenes mediante topografia de emisión de positrones (pet); composición farmaceutica; kit farmaceutico.
BR112020012712A8 (pt) Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos do referido composto para o tratamento de distúrbios do snc
MX369694B (es) Derivados de bencimidazol sulfonamidas como agonistas inversos del receptor gamma huerfano relacionado con el retinoide por gamma (t).
UY35199A (es) Nuevos derivados carbamato de ciclohexilo y quinuclidinilo que tienen actividad como agonistas beta2 adrenérgicos y como antagonistas muscarínicos M3
BR112017026535A2 (pt) composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto
PH12017501424B1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
BR112013004192A2 (pt) tratamento de hipertensão e/ou prevenção ou tratamento de falha do coração em um mamífero que recebe terapia de anticoagulante
CL2015001419A1 (es) Compuesto 6-((s)-1-{1-[5-(2-hidroxi-etoxi)-piridin-2-il]-1h-pirazol-3-il}-etil)-3h-1,3-benzotiazol-2-ona, antagonista del receptor ampa dependiente de tarp-gamma 8; composicion farmaceutica que lo comprende; metodo para tratar convulsiones epilepticas y dolor.
NZ721493A (en) Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
CL2008002316A1 (es) Compuestos heterociclicos nitrogenados que contienen fenilendiamina sustituida, inhibidores de la interaccion entre mdm2 y p53; procedimiento de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento del cancer.
UY34436A (es) Metodo de control del peso

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B07E Notice of approval relating to section 229 industrial property law
B06U Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements